We also need a robust pipeline of discovery thatll lead to new drug candidates for all different kinds of infections. So the limited population idea and the streamlining of Clinical Trials which wouldnt just decrease the time frame, it also decreases the cost and the, you know, the number of people needed, so it would do a number of things, that is one thing that we can do at fda that we think would be beneficial and would be beneficial for patients, but its not going to fix this problem we have of investment. Thank you, mr. Chairman. I yield back. I think that concludes this round of questioning. Well have followup questions, im sure, from members. Well send them to you and ask that you please respond. But, again, dr. Woodcock, you are a terrific witness. Thank you for your being so forthright, clear in your answers, and we will now take a three minute recess as we set up for the second panel. Thank you. The subcommittee willw reconvene on our second panel. Today we have, and ill them
/PRNewswire/ The "DevSecOps - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com s offering. Global DevSecOps Market to.